NV
NVCT.US Nuvectis Pharma Inc
- Market cap
- USD 696M
- P/E
- -
- P/B
- 5.50x
- ROE
- -45.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NVCT.US undervalued?
Graham numberThe Graham number of Nuvectis Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nuvectis Pharma Inc fundamental analysis
No fundamental analysis for Nuvectis Pharma Inc yet.
Nuvectis Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. i…
Full company profileNuvectis Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nuvectis Pharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 149K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -12.9M | -19.1M | -22.9M | - | - | - |
| Operating Income | -10.0K | -12.9M | -19.2M | -22.9M | -19.8M | -27.6M | -59.3M |
| EBITDA | -10.0K | -12.9M | -18.9M | -22.3M | -19.0M | -26.4M | -59.1M |
| Net Income | -10.0K | -12.9M | -18.8M | -22.3M | -19.0M | -26.4M | -57.5M |
| EPS | 0.00 | -1.01 | -1.48 | -1.43 | -1.11 | -1.21 | -1.95 |
| Balance Sheet | |||||||
| Total Assets | 6.66M | 6.66M | 20.4M | 19.2M | 18.6M | 31.7M | 141M |
| Total Liabilities | 10.0K | 17.7M | 6.19M | 6.98M | 8.89M | 13.3M | 14.2M |
| Shareholders' Equity | -10.0K | -11.0M | 14.2M | 12.2M | 9.71M | 18.4M | 127M |
| Cash & Short-term Investments | 5.74M | 5.74M | 20.0M | 19.1M | 18.5M | 31.6M | 141M |
| Cash Flow | |||||||
| Operating Cash Flow | 24.0K | -9.50M | -13.6M | -16.0M | -12.2M | -16.0M | -48.4M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 24.0K | -9.50M | -13.6M | -16.0M | -12.2M | -16.0M | -48.4M |
| Ratios | |||||||
| ROE | - | - | -132.1% | -182.4% | -195.6% | -143.6% | -45.4% |
| ROA | -0.2% | -193.6% | -92.1% | -116.0% | -102.1% | -83.4% | -40.8% |
| Net Profit Margin | - | - | -12,608.7% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nuvectis Pharma Inc dividends
Nuvectis Pharma Inc has not paid dividends in the last 6 fiscal years.
Who owns Nuvectis Pharma Inc
- Insiders 32.99%
- Institutions 33.86%
- Public & others 33.16%
- Shares outstanding 34.4M
- Free float 23.0M
Top funds holding NVCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 650K | 1.89% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 523K | 1.52% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 194K | 0.56% | -0.38% | Oct 2026 |
| Fidelity Small Cap Index | 187K | 0.54% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 ETF | 122K | 0.35% | +23.69% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 105K | 0.30% | +0.27% | Oct 2026 |
| Fidelity Extended Market Index | 94.0K | 0.27% | +11.42% | Sep 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 79.1K | 0.23% | -0.54% | Oct 2026 |
| iShares Micro-Cap ETF | 63.3K | 0.18% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 50.8K | 0.15% | +22.22% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 38.9K | 0.11% | +15.18% | Sep 2026 |
| Fidelity Total Market Index | 37.4K | 0.11% | +15.31% | Sep 2026 |
| Fidelity Series Total Market Index | 33.1K | 0.10% | +22.40% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 32.4K | 0.09% | +0.03% | Oct 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 26.9K | 0.08% | -5.94% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 26.6K | 0.08% | +17.17% | Sep 2026 |
| Vanguard Russell 2000 Growth ETF | 22.8K | 0.07% | +23.38% | Sep 2026 |
Top institutions holding NVCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 1.55M | 4.51% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.00M | 2.91% | +30.98% | Jun 2026 |
| Perceptive Advisors LLC | 1.00M | 2.91% | 0.00% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.00M | 2.91% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 872K | 2.54% | +32.22% | Jun 2026 |
| Iridian Asset Management LLC | 777K | 2.26% | +19.23% | Jun 2026 |
| Geode Capital Management, LLC | 432K | 1.26% | +12.54% | Jun 2026 |
| Sphera Funds Management Ltd. | 383K | 1.11% | 0.00% | Jun 2026 |
| Baldwin Brothers Inc | 382K | 1.11% | +0.90% | Jun 2026 |
| Occam Crest Management L.P. | 357K | 1.04% | -12.28% | Jun 2026 |
| Alyeska Investment Group, L.P. | 275K | 0.80% | 0.00% | Jun 2026 |
| State Street Corp | 248K | 0.72% | +49.05% | Jun 2026 |
| Susquehanna International Group, LLP | 217K | 0.63% | +106.38% | Jun 2026 |
| Kalehua Capital Management LLC | 200K | 0.58% | 0.00% | Jun 2026 |
| Avidity Partners Management LP | 200K | 0.58% | 0.00% | Jun 2026 |
| Northern Trust Corp | 147K | 0.43% | +18.12% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 128K | 0.37% | +11.07% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 118K | 0.34% | +28.37% | Jun 2026 |
| Citadel Advisors Llc | 116K | 0.34% | +47.32% | Jun 2026 |
| Oppenheimer & Co Inc | 73.6K | 0.21% | 0.00% | Jun 2026 |
Nuvectis Pharma Inc company profile
- Company name
- Nuvectis Pharma Inc
- Ticker
- NVCT.US
- Exchange
- USA Stocks
- Listed since
- Feb 4, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Fiscal year end
- December
- Address
- 1 Bridge Plaza, Fort Lee, NJ, United States, 07024
- Phone
- 201 614 3150
- Website
- nuvectis.com
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Nuvectis Pharma Inc management
4- Mr. Ron Bentsur M.B.A.Co-Founder, Chairman, CEO & President · born 1966
- Dr. Enrique Poradosu Ph.D.Co-Founder, Executive VP, Chief Scientific & Business Officer · born 1967
- Mr. Shay ShemeshCo-Founder, Executive VP, Chief Development & Operations Officer · born 1984
- Mr. Michael Carson CPAVice President of Finance · born 1976